Merck-Moderna mRNA Vaccine Cuts Melanoma Recurrence 44% in Phase 3

The randomized trial enrolled 157 patients post-resection and assigned them to 9 doses of individualized neoantigen mRNA vaccine plus standard pembrolizumab or pembrolizumab monotherapy. Primary endpoint was recurrence-free survival; secondary endpoints included distant-metastasis-free survival and safety. Absolute risk reduction reached 18 percentage points at 2.5 years, with consistent benefit across tumor mutational burden strata. This builds on the 2023 phase 2b results published in The Lancet and aligns with Merck’s parallel KRAS inhibitor data, indicating convergent progress in mutation-targeted and immune-education strategies.

Context from prior observational cohorts shows neoantigen vaccines historically failed in solid tumors due to poor immunogenicity; the current success hinges on lipid nanoparticle delivery and concurrent PD-1 blockade that sustains T-cell expansion. No overall survival data yet exist, and the trial remains open-label with industry sponsorship, raising questions about blinding and endpoint adjudication. Regulatory filings are anticipated in 2027.

Next steps include expansion into non-small-cell lung cancer and renal-cell carcinoma under similar adjuvant designs, with Moderna planning a 1,000-patient confirmatory study. Durability beyond three years and manufacturing scalability for individualized vaccines remain untested at commercial volumes.